Aurum Ventures MKI
Aurum Ventures MKI provides value added growth capital to exceptional entrepreneurs within the fields of life-sciences and clean-tech. While we focus on investing in unique, cutting edge technologies that will mature into successful business companies, our investments reflect our own values, so we prefer investing in companies that, through their sound commercial propositions, also contribute to the well-being of mankind. Our team is comprised of senior and experienced hands-on executives who work actively with the portfolio companies in enhancing their strategic and execution capabilities. We typically take a long-term approach, understanding that ventures in the life sciences and clean tech take time to mature and be successful.
Scopio Labs is a provider of Full Field Morphology dedicated to unlocking the potential of imaging and AI in hematology. Uncovering actionable insights from vast amounts of data readily available in the average blood sample and bone marrow aspirate, Scopio's solutions will aim to showcase thousands of cells at scale in high resolution, to enable new hematology diagnostic methods.
KidneyCure Ltd. is developing proprietary cell therapies aiming to prevent progression of Chronic Kidney Disease. The scientific basis and motivation for KidneyCure’s approach was provided by a world-renowned authority in Nephrology Prof. Benjamin Dekel, through genuinely pioneering research carried in his laboratory at Sheba Medical Center in Israel, one of the world’s leading medical centers. KidneyCure’s unique 3D renal cell cluster technology is expected to significantly delay the need for dialysis and transplantation and give millions of patients an opportunity to live longer higher quality lives.
Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.
LifeBond is a leader in the development and manufacturing of bio-surgical medical devices for tissue repair that are intended to improve the recovery of patients and to create an environment that supports the body’s natural healing process and promotes tissue repair. Of natural origin, elastic, adhesive, durable and yet absorbable, the company’s devices can be used to fill a long list of unmet surgical needs. LifeBond’s first product, LifeSeal™, is designed to provide staple-line reinforcement in bariatric and colorectal operations. It was recently studied in an international pilot clinical study in Europe. The company’s second pipeline product, LifeMesh™, a self-fixating hernia mesh, is in pre-clinical development. Other pipeline products include tissue adhesives and absorbable hemostats. LifeSeal™, LifeMesh™ and other LifeBond™ products are investigational and have not yet been approved for sale in the US or in any other market. For more information please visit use at: www.life-bond.com
CorAssist is a clinical stage medical device company committed to developing innovative therapeutic products for treating Heart Failure with Preserved Ejection Fraction. The company's proprietary technology enables the first implantation of a device that directly improves cardiac diastolic function. CORolla®, is an elastic self-expanding internal spring-like device implanted inside the left ventricular, through a Transapical or percutaneous procedure. The device assists diastolic function by improving diastolic dynamics and filling performance, and does not require an external power source. ImCardia® , the company's first product, is an elastic self-expanding device that is attached to the external left ventricular surface, through a simple off pump procedure.
BPT is developing and commercializing advanced membranes-based separation solutions addressing the unique needs of the water and wastewater treatment for key industrial processes. BPT patented chemically-stable membrane technology enable customers in the landfill, mining, chemical, biopharma and food industries to comply with the environmental regulations, reuse water and reduce production costs. BPT membranes are field proven to enable lowest cost reclamation of some of the most aggressive and vexing industrial waste water streams.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.